Trial Profile
A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2021
Price :
$35
*
At a glance
- Drugs Diroximel-fumarate (Primary) ; Dimethyl fumarate
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms EVOLVE-2; EVOLVE-MS-2
- Sponsors Alkermes plc; Biogen
- 16 Nov 2021 According to a Biogen media release, the European Commission (EC) has granted marketing authorization for VUMERITY (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS).
- 15 Oct 2021 Results comparing the impact of dose titration on gastrointestinal tolerability presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 15 Oct 2021 Results of post hoc analysis of incidence, severity, and duration of flushing and flushing-related treatment-emergent adverse events with Diroximel fumarate versus dimethyl fumarate over 5 weeks, presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis